Search results for "OUTCOME"

showing 10 items of 5148 documents

Robotic treatment of colorectal endometriosis: technique, feasibility and short-term results

2012

background: Deep infiltrating endometriosis (DIE) is a complex disease that impairs the quality of life and the fertility of women. Since a medical approach is often insufficient, a minimally invasive approach is considered the gold standard for complete disease excision. Roboticassisted surgery is a revolutionary approach, with several advantages compared with traditional laparoscopic surgery. methods: From March 2010 to May 2011, we performed 22 consecutive robotic-assisted complete laparoscopic excisions of DIE endometriosis with colorectal involvement. All clinical data were collected by our team and all patients were interviewed preoperatively and 3 and 6 months post-operatively and ye…

AdultLaparoscopic surgerymedicine.medical_specialtyAdolescentmedicine.medical_treatmentEndometriosisEndometriosisIleostomyPostoperative ComplicationsROBOTIC SURGERYLaparotomymedicineHumansLaparoscopyRetrospective Studiesmedicine.diagnostic_testbusiness.industryRehabilitationColostomyObstetrics and GynecologyRoboticsMiddle AgedDebulkingmedicine.diseaseSettore MED/40 - Ginecologia E OstetriciaSurgeryRectal DiseasesTreatment OutcomeReproductive MedicineFemaleLaparoscopySegmental resectionbusinessdeep endometriosis / colorectal endometriosis / robotic-assisted laparoscopy
researchProduct

Laparoscopic-ultrasonographic combined technique for the creation of a neovagina in Mayer-Rokitansky-Kuster-Hauser syndrome

1996

Objective To create a neovagina using a combined laparoscopic and ultrasonographic technique in Mayer-Rokitansky-Kuster-Hauser syndrome by modification of Vecchietti's operation. Design Case report. Setting Division of Physiopathology of Reproduction, University of Palermo, Palermo, Italy. Main Outcome Measure(s) The advancement of the needle from the pseudohymen, through the vesicorectal space using a triple contrast ultrasonographic technique. Result(s) The ultrasonographic scanning guides the accurate transit from external genitalia to the peritoneal cavity. Conclusion(s) This original approach allowed a safe and rapid creation of a neovagina in a case of Mayer-Rokitansky-Kuster-Hauser s…

AdultLaparoscopic surgerymedicine.medical_specialtymedicine.medical_treatmentEndoscopic surgeryCombined techniquemedicineHumansAbnormalities MultipleMayer-Rokitansky-Kuster-Hauser SyndromePeritoneal CavityUltrasonographymedicine.diagnostic_testbusiness.industryUterusOutcome measuresObstetrics and GynecologyGenitalia FemaleSyndromeSurgeryEndoscopyReproductive MedicineExternal genitaliaVaginaFemaleLaparoscopyOperative laparoscopybusinessFertility and Sterility
researchProduct

How to select early-stage cervical cancer patients still suitable for laparoscopic radical hysterectomy: a propensity-matched study

2020

Background: Recently, it was reported that minimally invasive surgery (MIS) has a negative impact on early-stage cervical cancer (ECC) patient survival. At the same time, advantages of MIS regarding quality of life and low rate of intra- and postoperative complications are well known. Therefore, it is essential to select patients who may benefit from MIS without worsening their oncologic outcomes. The aim of this study is to investigate which pathological factors could guide surgeons’ choice about the best approach in ECC. Patients and Methods: Patients with 2009 FIGO stage from IA1 with lymphovascular space invasion (LVSI) to IB1/IIA1 treated by open or laparoscopic surgery were judged eli…

AdultLaparoscopic surgerymedicine.medical_specialtymedicine.medical_treatmentlaparoscopyUterine Cervical NeoplasmsHysterectomyDisease-Free Survivalopen surgeryYoung Adult03 medical and health sciences0302 clinical medicineSurgical oncologymedicineHumansMinimally Invasive Surgical ProceduresRadical HysterectomyPropensity ScoreLaparoscopyGrading (tumors)minimally invasive surgeryAgedNeoplasm StagingRetrospective StudiesAged 80 and overCervical cancermedicine.diagnostic_testbusiness.industryParametrialCervical cancer; laparoscopy; minimally invasive surgery; open surgery; radical hysterectomy; tumor diameterHazard ratioMiddle Agedmedicine.diseaseSurgerySurvival RateTreatment OutcomeSettore MED/40 - GINECOLOGIA E OSTETRICIAItalyOncology030220 oncology & carcinogenesisradical hysterectomyCervical cancerFemale030211 gastroenterology & hepatologySurgerytumor diameterbusiness
researchProduct

Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015

2019

 The urgent need in HCV-infected patients with liver disease mandated the rapid implementation of IFN-free DAA combination therapies following their regulatory approval in 2014 and 2015 without full knowledge of the optimal combinations and regimens. Investigating the evolution of the DAA utilization patterns and treatment outcomes could provide learnings for future situations. This was an analysis of a prospective observational database from the German Hepatitis C Registry (DHC-R) covering a period from May 2014 to September 2015. Adult patients had evidence of chronic HCV GT1 or GT4 infection and were treated with an IFN-free combination regimen of simeprevir (SMV) + sofosbuvir (SOF) or o…

AdultLedipasvirSimeprevirmedicine.medical_specialtyDaclatasvirSustained Virologic ResponseSofosbuvirHepacivirusAntiviral Agents03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineHumansMedicineProspective StudiesRegistries030212 general & internal medicineFluorenesDasabuvirbusiness.industryGastroenterologyHepatitis C ChronicHepatitis COmbitasvirDrug CombinationsRegimenTreatment OutcomechemistryParitaprevirBenzimidazolesDrug Therapy Combination030211 gastroenterology & hepatologySofosbuvirbusinessmedicine.drugZeitschrift für Gastroenterologie
researchProduct

The role of adiponectin and leptin in the treatment of ovarian cancer patients

2019

Introduction: Ovarian cancer is most frequently detected in the advanced stage. Although its pathogenesis is not fully elucidated, it is assumed that body susceptibility and hormonal disorders are responsible. The role of some cytokines as predictors in the treatment process is still investigated. The aim of the study was to determine the relationship of adiponectin and leptin with the disease severity and response to chemotherapy. Material and methods: Forty-three ovarian cancer patients were treated by systemic treatment. Patients received 5–7 cycles of chemotherapy — paclitaxel/carboplatin with or without bevacizumab. Using standard ELISA kits before and after chemotherapy, adiponectin a…

AdultLeptinmedicine.medical_specialtyPaclitaxelBevacizumabEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAdipokine030209 endocrinology & metabolismGastroenterologyCarboplatin03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyBlood serumInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedAged 80 and overOvarian NeoplasmsChemotherapyAdiponectinbusiness.industryLeptinMiddle Agedmedicine.diseaseCarboplatinBevacizumabTreatment OutcomechemistryFemaleAdiponectinOvarian cancerbusinessBiomarkershormones hormone substitutes and hormone antagonistsmedicine.drugEndokrynologia Polska
researchProduct

HCV viraemia is more important than genotype as a predictor of response to interferon in sicily (Southern Italy)

1996

Abstract Background/Aims: To investigate host- and virus-related factors predictive of early and sustained alanine aminotransferase normalization after interferon therapy for HCV-related chronic liver disease, in an area where genotype 1 is highly prevalent. Methods: We studied 100 patients with HCV-RNA positive chronic liver disease (73 chronic hepatitis and 27 cirrhosis) undergoing alpha-interferon treatment. Thirty-four patients had an early response but relapsed, 15 patients remained into sustained response for at least 12 months after therapy, and 51 patients did not respond. Serum HCV-RNA levels were assessed by bDNA (Chiron), and genotype by LiPA (Innogenetics) and by sequencing of t…

AdultLiver CirrhosisMaleCirrhosisGenotypeHepatitis C virusMolecular Sequence DataAlpha interferonChronic liver diseasemedicine.disease_causeAntiviral AgentsGenotypePrevalenceBDNA testmedicineHumansViremiaSicilyInterferon alfaBase SequenceHepatologybusiness.industryInterferon-alphaAlanine TransaminaseHepatitis CMiddle Agedmedicine.diseaseHepatitis CTreatment OutcomeLiverChronic DiseaseImmunologyNucleic Acid ConformationFemalebusinessmedicine.drugJournal of Hepatology
researchProduct

Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis

2009

GOALS AND BACKGROUND: The multikinase inhibitor sorafenib provides survival benefit for patients with advanced hepatocellular carcinoma (HCC) and liver cirrhosis (LCI) Child-Pugh A. We report our experiences with sorafenib in advanced HCC, particularly in patients with LCI Child-Pugh B/C, where only limited data are available in regard to safety and efficacy of sorafenib. METHODS: Thirty-four patients with advanced HCC were treated with sorafenib regardless of liver function and prior anticancer therapy. Adverse events (AEs) were graded using Common Toxicity Criteria version 3.0, tumor response was assessed according to Response Evaluation Criteria in Solid Tumors. RESULTS: Fifteen patients…

AdultLiver CirrhosisMaleNiacinamideSorafenibmedicine.medical_specialtyCarcinoma HepatocellularTime FactorsCirrhosisPyridinesAntineoplastic AgentsKaplan-Meier EstimateRisk AssessmentSeverity of Illness IndexGastroenterologyInternal medicinemedicineCarcinomaHumansProspective StudiesProtein Kinase InhibitorsAgedAged 80 and overbusiness.industryPatient SelectionPhenylurea CompoundsBenzenesulfonatesLiver NeoplasmsGastroenterologyCancerMiddle AgedSorafenibmedicine.diseasedigestive system diseasesSurgeryTreatment OutcomeResponse Evaluation Criteria in Solid TumorsHepatocellular carcinomaConcomitantFemaleLiver functionbusinessmedicine.drugJournal of Clinical Gastroenterology
researchProduct

Prognostic factors and outcomes of patients with hepatocellular carcinoma in non-cirrhotic liver

2012

To report the outcome of patients with hepatocellular carcinoma (HCC) in non-cirrhotic liver depending on the mode of primary treatment and to define clinicopathological factors influencing patients' prognosis.A retrospective analysis of an unselected cohort of 105 patients was performed. Overall survival (OS) was estimated by the Kaplan-Meier method and potentially prognostic factors were analyzed in Cox regression models.OS of the whole cohort at 1, 3, and 5 years was 66%, 47%, and 29%, respectively. Tobacco consumption, ECOG0, macroscopic vascular invasion, continuous tumor diameter, and treatment other than resection were predictors of decreased OS in the whole cohort. Resection was per…

AdultLiver CirrhosisMaleOncologymedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentAntineoplastic AgentsRisk FactorsInternal medicinemedicineCarcinomaHepatectomyHumansSurvival analysisAgedNeoplasm StagingRetrospective StudiesAged 80 and overProportional hazards modelbusiness.industryLiver NeoplasmsGastroenterologyRetrospective cohort studyMiddle AgedPrognosismedicine.diseaseSurvival AnalysisBCLC StageTreatment OutcomeLiverHepatocellular carcinomaCohortFemaleHepatectomybusinessFollow-Up StudiesScandinavian Journal of Gastroenterology
researchProduct

Treatment of chronic hepatitis B in sub-Saharan Africa: 1-year results of a pilot program in Ethiopia

2018

Background The World Health Organization has set an ambitious goal of eliminating viral hepatitis as a major public health threat by 2030. However, in sub-Saharan Africa, antiviral treatment of chronic hepatitis B (CHB) is virtually unavailable. Herein, we present the 1-year results of a pilot CHB treatment program in Ethiopia. Methods At a public hospital in Addis Ababa, CHB patients were treated with tenofovir disoproxil fumarate based on simplified eligibility criteria. Baseline assessment included liver function tests, viral markers, and transient elastography (Fibroscan). Changes in laboratory markers were analyzed using Wilcoxon signed-rank tests. Adherence to therapy was measured by …

AdultLiver CirrhosisMalemedicine.medical_specialtyAdolescentEpidemiologylcsh:MedicinePilot ProjectsAntiviral therapymedicine.disease_causeAntiviral AgentsYoung Adult03 medical and health sciencesHepatitis B Chronic0302 clinical medicineChronic hepatitisInternal medicineEpidemiologymedicineHumansPilot program030212 general & internal medicineViral hepatitisTenofovirHepatitis B virusmedicine.diagnostic_testbusiness.industryPublic healthlcsh:RGeneral MedicineMiddle AgedViral Loadmedicine.diseaseResource-limited settingsTreatment Adherence and ComplianceTreatment OutcomeFemale030211 gastroenterology & hepatologyEthiopiaTransient elastographybusinessLiver function testsViral hepatitisBiomarkersFollow-Up StudiesResearch ArticleBMC Medicine
researchProduct

Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma

2013

Abstract Background Transarterial chemoembolisation (TACE) is an effective treatment for unresectable hepatocellular carcinoma (HCC), but can cause severe toxicity. Aim To identify predictive factors of severe TACE-related toxicity in patients with unresectable HCC. Methods All HCC patients who underwent TACE at the Dijon University Hospital between 2008 and 2011 were included in this retrospective study. Severe TACE-related toxicity was defined as the occurrence of any adverse event grade ≥4, or any adverse event that caused a prolongation of hospitalisation of >8 days, or any additional hospitalisation within 1 month after TACE. Factors predicting toxicity were identified using a logistic…

AdultLiver CirrhosisMalemedicine.medical_specialtyCarcinoma HepatocellularMultivariate analysisLogistic regressionGastroenterologyCohort StudiesHepatitis B ChronicLiver Cirrhosis AlcoholicRisk FactorsInternal medicinemedicineHumansIn patientAspartate AminotransferasesChemoembolization TherapeuticAdverse effectAgedRetrospective StudiesAged 80 and overHepatologybusiness.industryLiver NeoplasmsGastroenterologyRetrospective cohort studyAcute Kidney InjuryHepatitis C ChronicLiver Failure AcuteMiddle Agedmedicine.diseaseUniversity hospitalTumor BurdenSurgeryLogistic ModelsTreatment OutcomeDoxorubicinHepatic EncephalopathyHepatocellular carcinomaMultivariate AnalysisToxicityFemaleChemical and Drug Induced Liver InjuryIdarubicinbusinessDigestive and Liver Disease
researchProduct